( September 25, 2023, 03:51 GMT | Official Statement) -- MLex Summary: Simcere Pharmaceutical’s acquisition of Beijing Tobishi Pharmaceutical has received conditional antitrust approval from China’s State Administration for Market Regulation. According to a decision published by the regulator, the deal hadn’t met the prescribed notification thresholds, but might restrict competition in the Chinese market for batroxobin injections. To ease competition concerns, Simcere must terminate its exclusive supply agreement with DSM Nutritional Products, which made Simcere the sole batroxobin supplier within China. Among other remedies, Simcere must also divest its batroxobin injection business that is under research and development, supply batroxobin to the buyer, and assist the buyer in obtaining the pharmaceutical ingredient directly from DSM.SAMR’s decision follows:...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.